Terms: = Ovarian cancer AND PTPRC, LCA, 5788, ENSG00000081237, T200, GP180, B220, LY5, CD45
93 results:
1. A Microfluidics Approach for ovarian cancer Immune Monitoring in an Outpatient Setting.
Libbrecht S; Vankerckhoven A; de Wijs K; Baert T; Thirion G; Vandenbrande K; Van Gorp T; Timmerman D; Coosemans A; Lagae L
Cells; 2023 Dec; 13(1):. PubMed ID: 38201211
[TBL] [Abstract] [Full Text] [Related]
2. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
3. Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype.
Vanhaver C; Aboubakar Nana F; Delhez N; Luyckx M; Hirsch T; Bayard A; Houbion C; Dauguet N; Brochier A; van der Bruggen P; Bruger AM
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37931958
[TBL] [Abstract] [Full Text] [Related]
4. Identification of two immune subtypes and four hub immune-related genes in ovarian cancer through multiple analysis.
Tang Q; Zhang H; Tang R
Medicine (Baltimore); 2023 Oct; 102(40):e35246. PubMed ID: 37800814
[TBL] [Abstract] [Full Text] [Related]
5. Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions.
Sajman J; Yakovian O; Unger Deshet N; Almog S; Horn G; Waks T; Globerson Levin A; Sherman E
Cells; 2023 Sep; 12(18):. PubMed ID: 37759484
[TBL] [Abstract] [Full Text] [Related]
6. Cellular and extracellular vaginal changes following murine ovarian removal.
McCracken JM; Calderon GA; Le QN; Faruqui NM; Balaji S; Hakim JCE
Physiol Rep; 2023 Aug; 11(15):e15762. PubMed ID: 37549960
[TBL] [Abstract] [Full Text] [Related]
7. Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer.
Bartl T; Alberts A; Papadopoulos SC; Wolf A; Muellauer L; Hofstetter G; Grimm C; Cacsire Castillo-Tong D
Int J Gynecol Cancer; 2023 Sep; 33(9):1419-1426. PubMed ID: 37094966
[TBL] [Abstract] [Full Text] [Related]
8. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
9. Molecular targets of metformin against ovarian cancer based on network pharmacology.
Guo JY; Wang YJ; Li SQ; Wu YP
Chem Biol Drug Des; 2023 Jul; 102(1):88-100. PubMed ID: 36977503
[TBL] [Abstract] [Full Text] [Related]
10. Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade ovarian Serous Carcinoma.
Ruano APC; Gadelha Guimarães AP; Braun AC; Flores BCTCP; Tariki MS; Abdallah EA; Torres JA; Nunes DN; Tirapelli B; de Lima VCC; Fanelli MF; Colombo PE; da Costa AABA; Alix-Panabières C; Chinen LTD
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499015
[TBL] [Abstract] [Full Text] [Related]
11. The role of bile acids in carcinogenesis.
Režen T; Rozman D; Kovács T; Kovács P; Sipos A; Bai P; Mikó E
Cell Mol Life Sci; 2022 Apr; 79(5):243. PubMed ID: 35429253
[TBL] [Abstract] [Full Text] [Related]
12. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.
Matsuzaki J; Lele S; Odunsi K; Tsuji T
Oncoimmunology; 2022; 11(1):2020983. PubMed ID: 35003898
[TBL] [Abstract] [Full Text] [Related]
13. Littoral cell angioma disguised as huge ovarian cyst: A thought to ponder.
Nur Bazlaah B; Khairuzi S; Syariz Ezuan S; Ismayudin I; Poobalan K; Adzwani M; Hidhaya S
Med J Malaysia; 2021 Nov; 76(6):921-923. PubMed ID: 34806686
[TBL] [Abstract] [Full Text] [Related]
14. Stem-like tumor cells and proinflammatory cytokines in the ascitic fluid of ovarian cancer patients.
Gening SO; Abakumova TV; Antoneeva II; Rizvanov AA; Gening TP; Gafurbaeva DU
Klin Lab Diagn; 2021 May; 66(5):297-303. PubMed ID: 34047516
[TBL] [Abstract] [Full Text] [Related]
15. Infiltration of Immune Competent Cells into Primary Tumors and Their Surrounding Connective Tissues in Xenograft and Syngeneic Mouse Models.
Metzen M; Bruns M; Deppert W; Schumacher U
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921688
[TBL] [Abstract] [Full Text] [Related]
16. Glutamine deficiency promotes stemness and chemoresistance in tumor cells through DRP1-induced mitochondrial fragmentation.
Prasad P; Ghosh S; Roy SS
Cell Mol Life Sci; 2021 May; 78(10):4821-4845. PubMed ID: 33895866
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic and Clinical Value of Interleukin 6 and cd45
Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
[TBL] [Abstract] [Full Text] [Related]
18. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells.
Payne KK; Mine JA; Biswas S; Chaurio RA; Perales-Puchalt A; Anadon CM; Costich TL; Harro CM; Walrath J; Ming Q; Tcyganov E; Buras AL; Rigolizzo KE; Mandal G; Lajoie J; Ophir M; Tchou J; Marchion D; Luca VC; Bobrowicz P; McLaughlin B; Eskiocak U; Schmidt M; Cubillos-Ruiz JR; Rodriguez PC; Gabrilovich DI; Conejo-Garcia JR
Science; 2020 Aug; 369(6506):942-949. PubMed ID: 32820120
[TBL] [Abstract] [Full Text] [Related]
19. An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.
Bellizzi AM
Adv Anat Pathol; 2020 May; 27(3):114-163. PubMed ID: 32205473
[TBL] [Abstract] [Full Text] [Related]
20. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract] [Full Text] [Related]
[Next]
